BEDFORD, Mass.--(BUSINESS WIRE)--Oct. 9,
2006--Cambridge Heart, Inc. (OTCBB-CAMH) today announced today that its President and CEO,
David A. Chazanovitz, will present at the Rodman & Renshaw 8th Annual Healthcare
Conference on Monday, November 6, 2006 at 2:30 PM EST. The conference is being held
November 6 to 8 at the New York Palace Hotel in New York City.Mr. Chazanovitz will be
discussing recent business highlights. The presentation will be webcast and can be
accessed on http://www.wsw.com/webcast/rrshq10/camh.ob.
About Cambridge Heart
Cambridge Heart is engaged in the research, development and commercialization of
products for the non-invasive diagnosis of cardiac disease. Using innovative technologies,
the Company is addressing such key problems in cardiac diagnosis as the identification of
those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary
technology, Microvolt T-Wave Alternans, and are the first diagnostic tools cleared by the
U.S. Food and Drug Administration to non-invasively measure microvolt levels of T-wave
alternans. The Company, founded in 1990, is based in Bedford, Massachusetts and is traded
on the OTCBB under the symbol CAMH. Cambridge Heart can be found on the World Wide Web at
www.cambridgeheart.com
About the Cambridge Heart Microvolt T-Wave Alternans Test
The Cambridge Heart Microvolt T-Wave Alternans Test measures extremely subtle
beat-to-beat fluctuations in a person's heartbeat called T-wave alternans. These tiny
heartbeat variations - measured at one millionth of a volt - are detected in any clinical
setting where titration of the heart rate is possible. The preparation for the test
consists of placing proprietary sensors on a patient's chest. Extensive clinical research
has shown that patients with symptoms of, or who are at risk of, life threatening
arrhythmias that test positive for T-wave alternans are at significant risk for subsequent
sudden cardiac events including sudden death, while those who test negative are at minimal
risk.
CONTACT: Cambridge Heart, Inc.
Roderick de Greef, 781-271-1200 ext 231
CFO
roderickd@cambridgeheart.com
or
Consulting For Strategic Growth
Stan Wunderlich, 800-625-2236
info@cfsg1.com
SOURCE: Cambridge Heart, Inc.